论文部分内容阅读
本文研究了一种重组人ＴＮＦα衍生物（ｒｈＴＮＦαＤ１１ａ）对小鼠Ｌｅｗｉｓ肺癌的抗肿瘤作用。同时与原型重组人ＴＮＦα（ｒｈＴＮＦα）的抗肿瘤作用进行了比较，并对它们全身给药和局部给药的抗瘤效果作了对比。Ｃ５７ＢＬ／６小鼠接种肿瘤细胞后ｄ７，将ｒｈＴＮＦαＤ１１ａ和ｒｈＴＮＦα以高、中、低三种剂量分别连续肌肉注射４ｄ，或瘤内注射３ｄ，停药后１ｄ处死动物，根据抑瘤率进行疗效评价。结果表明，ｒｈＴＮＦαＤ１１ａ各剂量组的抑瘤率均显著高于同样剂量的ｒｈＴＮＦα；两种ＴＮＦ瘤内注射的抗肿瘤作用均明显优于肌肉注射。
This article studied the antitumor effect of a recombinant human TNFα derivative (rhTNFαD11a) on Lewis lung cancer in mice. At the same time, compared with the prototype anti-tumor effect of recombinant human TNFα (rhTNFα), and compared their anti-tumor effect of systemic administration and local administration. After C57BL/6 mice were inoculated with tumor cells for d7, rhTNFαD11a and rhTNFα were continuously intramuscularly injected for 4 days at high, medium and low doses, or injected intratumorally for 3 days. Animals were sacrificed 1 d after discontinuation. The curative effect was evaluated according to the rate of tumor inhibition. . The results showed that the inhibition rate of rhTNFαD11a in each dose group was significantly higher than that of the same dose of rhTNFα; the antitumor effect of intratumoral injection of both TNF was significantly better than that of intramuscular injection.